Bacil Pharma Ltd (BACPHAR) — shareholding pattern, promoter holding, financials and share price
About Bacil Pharma Ltd (BACPHAR)
Bacil Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BACPHAR and on the BSE under scrip code 524516. Its ISIN is INE711D01018.
Incorporated in 1987, Bacil Pharma Ltd is in Pharmaceutical business [1]
Bal Pharma is a leading Indian pharmaceutical company engaged in the production and distribution of prescription drugs, branded formulations, APIs, and OTC products. Their operations extend throughout India with a well-established distribution network.
The company specializes in diverse therapeutic areas, including anti-infectives, pain management, respiratory care, and women's health, showcasing a wide range of products under various prominent brands.
Listed peers in Pharmaceuticals: Ajooni Biotech Ltd, Vineet Laboratories Ltd, Vasundhara Rasayans Ltd, Biofil Chemicals & Pharmaceuticals Ltd, Kabra Drugs Ltd, Vivimed Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹38.5 a share on 10 Jul 2026, Bacil Pharma Ltd (BACPHAR) was valued at a price-to-earnings ratio of 41.24x against an industry P/E of 36.41x and a price-to-book of 2.17x on a book value of ₹17.72 per share as of Mar 2025. Solomo computes return on equity of 5.27% and return on capital employed of 3.87% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 41.24x
- Industry P/E
- 36.41x
- P/B
- 2.17x
- EPS (TTM)
- ₹0.93
- Book value / share
- ₹17.72
- ROE
- 5.27%
- ROCE
- 3.87%
- ROA
- 5.23%
- Debt / equity
- 0.01x
- Dividend yield
- 0%
- 52-week range
- ₹26.69 – ₹61.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Bacil Pharma Ltd (BACPHAR) reported net profit of ₹1.56 crore and earnings per share of ₹1.09. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, net profit ₹0.62 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0 | 0 | 0 | 0 | 0 |
| Net profit (₹ cr) | -3.86 | -0.1 | -0.06 | 0.4 | 1.56 |
| EPS (₹) | -6.55 | -0.17 | -0.1 | 0.28 | 1.09 |
| Measure | 1Y |
|---|---|
| Profit growth | 766.67% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 0% of Bacil Pharma Ltd (BACPHAR) (unchanged from the previous quarter). Market capitalisation was ₹55 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: VICKY PRATAPBHAI SHAH 16.59%, NIKITA HIREN PATEL 10.07%, MANUBHAI AMRUTLAL SHAH 9.86%, CHHAYA GAURANG SHAH 6.66%, NIRAJ RAJNIKANT SHAH 6.44%, MANMOHAN JAGDISHPRASAD GHUWALEWALA 4.18%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 0% | - | - | - | 100% |
| Mar 2026 | 0% | - | - | - | 100% |
| Dec 2025 | 0.08% | - | - | - | 99.92% |
| Sep 2025 | 0.08% | - | - | - | 99.92% |
| Jun 2025 | 0.2% | - | - | - | 99.8% |
| Mar 2025 | 0.2% | - | - | - | 99.8% |
| Dec 2024 | 10.6% | - | - | - | 89.4% |
| Sep 2024 | 20.7% | - | - | - | 79.3% |